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Abstract
Misoprostol is a synthetic analogue of prostaglandin E1 that is administered to women at high doses to induce uterine
contractions for early pregnancy termination and at low doses to aid in cervical priming during labor. Because of the known
teratogenic effects of misoprostol when given during gestation and its effects on axonal growth in vitro, we examined
misoprostol for its potential as a neurodevelopmental toxicant when administered to neonatal C57BL6/J mice. Mice were
injected subcutaneously (s.c.) with 0.4, 4 or 40 mg/kg misoprostol on postnatal day 7, the approximate developmental stage
in mice of human birth, after which neonatal somatic growth, and sensory and motor system development were assessed.
These doses were selected to span the range of human exposure used to induce labor. In addition, adult mice underwent a
battery of behavioral tests relevant to neurodevelopmental disorders such as autism including tests for anxiety, stereotyped
behaviors, social communication and interactions, and learning and memory. No significant effects of exposure were found
for any measure of development or behavioral endpoints. In conclusion, the results of the present study in C57BL/6J mice
do not provide support for neurodevelopmental toxicity after misoprostol administration approximating human doses and
timed to coincide with the developmental stage of human birth.
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Introduction
The incidence of autism spectrum disorders (ASD) has increased
over the last few decades [1–6]. In the majority of these cases the
cause of ASD is unknown (idiopathic autism) but evidence is
accumulating that environmental factors may contribute to the
etiology of autism [4,7–10]. Environmental factors under inves-
tigation include proximity to highways and associated air pollution
[11], pesticide exposures [12,13], maternal vitamin supplementa-
tion [14,15], parental age [16–18], and maternal exposure to
pharmacological agents during pregnancy and perinatal periods
[19–21]. Pharmacological agents of interest include misoprostol
[22–24], thalidomide [23], valproic acid (VPA) [25,26], and
tertbulaline [27,28].
Misoprostol is a synthetic prostaglandin E1 analogue that was
initially developed to treat peptic ulcers through its ability to
decrease gastric acid secretion and increase mucosal protective
properties [29,30]. It was later determined that misoprostol was
capable of producing cervical ripening and uterine contractions in
pregnant women [31–33]. Because of these latter properties
misoprostol is now commonly used in obstetric and gynecological
practices to induce labor, or if administered at higher doses early
in gestation to terminate pregnancy.
The use of misoprostol however is not without risk. There is
evidence that prenatal exposure to high doses of misoprostol
during the first or second trimester can lead to the occurrence of
Mo ¨bius Syndrome, a disorder characterized by congenital palsy of
the 6
th and 7
th cranial nerves [23]. Further in a study by
Stro ¨mland et al. 7 out of 22 children with Mo ¨bius syndrome also
displayed autistic characteristics [34], a significantly higher
incidence then that seen in the general population [35]. This
relationship between misoprostol exposure and the development of
autistic features in Mo ¨bius Syndrome suggests the possibility that
the use of misoprostol may be a developmental risk factor in
autism [23,36].
Dufour-Rainfray et al. have recently suggested that through
different mechanisms several teratogens, including misoprostol,
are able to modulate the expression of genes leading to
developmental disorders with autistic like characteristics [36].
They theorize that altered gene expression can lead to deregula-
tion of important neurodevelopmental processes, the same
processes which have been shown to involve proteins encoded
by genes mutated or altered in some patients with autism [37,38].
Further recent findings by Tamiji et al. indicate that exposure to
misoprostol can alter calcium homeostasis in nerve growth cones
of mouse Neuro-2a cells, as well as cause retraction of developing
neurites, providing a possible cellular mechanism by which
misoprostol could influence development of the nervous system
[39,40]. Lastly, prostaglandins, including misoprostol, are known
to regulate a wide variety of immunological processes, including
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brain function and development are highly influenced by cytokine
activity [45–47] and immune system abnormalities have been
linked to autism [48–51], the possibility that misoprostol and other
prostaglandins administered during labor may be a risk factor for
ASD is a concern.
Preliminary findings from the CHARGE (CHildhood Autism Risk
from Genetics and the Environment) Study, an ongoing case-control
study of autism risk, reported that use of vaginal prostaglandins,
including misoprostol, was more common among mothers of
children with autism compared with controls, although this
association failed to achieve statistical significance [52].
Therefore, we carried out the following study examining
neonatal misoprostol exposure in mice for evidence of neurode-
velopmental toxicity. In this study C57BL6/J mice were exposed
to 0.4, 4, and 40 mg/kg misoprostol, s.c. on postnatal day (PND) 7.
These doses were selected to span the range of clinical doses
(,0.33–35 mg/kg based on an average 75 kg body weight) used to
induce labor [53,54]. PND 7 was chosen because it approximates
the developmental stage at human birth [55] when misoprostol is
typically given to induce labor. A battery of behavioral tests was
then administered to mice over the course of development to assess
somatic growth as well as neurodevelopmental endpoints relevant
to ASD, including social interactions, stereotypic behaviors,
anxiety, and learning and memory [56–58].
Materials and Methods
Chemicals
Misoprostol (.98% purity) was purchased from Cayman
Chemical Co. (Ann Arbor, MI). Following the laboratory
procedures provided by the supplier, a solvent exchange from
methyl acetate to dimethyl sulfoxide (DMSO. $99.9% purity) was
conducted for preferred storage as recommended by Cayman
Chemical Co. Dosing solutions were diluted from a stock solution
with sterile physiological saline. Exposure to DMSO through
administration of misoprostol did not exceed 0.722 mg/kg. This
level of exposure is well below the levels used in studies which
report neuroprotective properties of DMSO [59,60].
Animals
Adult male and female C57BL6/J mice were purchased from
Jackson Laboratory (Bar Harbor, ME) and maintained by the
Center for Laboratory Animal Research (CLAS), at University of
California, Davis. Mice were fed standard mouse chow (LabDiet,
5001 Rodent Diet) and were maintained on a 14 h light/10 h dark
cycle, with the light cycle between 7AM to 9PM. Ambient
temperature was maintained between 6862uF and humidity
between 40–60%.
After 1 week of acclimatization mice were mated and dams were
checked daily for the presence of seminal plugs, after which the
cages housing the pregnant dams were checked daily for birth of
litters by viewing cage bottoms. On postnatal (PND) 7 pups in
each litter were injected subcutaneously in the nape of the neck
with either saline vehicle or 0.4, 4 or 40 mg/kg misoprostol. A
within litter design was used, and when possible the full range of 4
doses for males and 4 doses for females was represented within a
litter (i.e., 4 treatments by sex=8 injected mice). However, with
litter sizes less than 8, pups were randomly assigned to one of the 4
treatments groups, with no single dose for males or females
repeated within a litter. A total of 12 litters were used in this study.
This allowed us to achieve final treatment group sizes of n=16 (8
male and 8 female mice per treatment group) with the same
animals used for all behavioral testing. Mice were then marked for
identification using non-toxic foot tattoos (Ketchum Manu. Inc.,
Brockville, ON, Canada).
All experimental procedures and protocols using mice were
approved by the University of California, Davis Institutional
Animal Care and Use Committee (IACUC) under protocol
#16001.
Behavioral Testing
Behavioral tests are described in the order that they were
conducted, along with the approximate ages of the mice. All tests
were conducted during the light phase of the light/dark cycle.
Tests conducted prior to weaning on PND 21 were administered
between 7am and 12pm. Tests conducted after weaning were
administered between 12pm and 5pm.
1. Growth and Reflex Assessments (PNDs 8, 14, 18). Us-
ing a test battery described previously [61], somatic, sensory and
motor development were assessed. Briefly, pups were removed
Figure 1. Neurodevelopmental composite score (sensory and
motor development) for the four treatment groups. No group
differences were statistically significant.
doi:10.1371/journal.pone.0038911.g001
Figure 2. Number of bouts of ultrasonic vocalizations (USV) on
postnatal days 9, 11 13 & 17. No group differences were statistically
significant.
doi:10.1371/journal.pone.0038911.g002
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were then individually observed using the following tests: righting
reflex, cliff aversion, needle grasp, visual placing, vibrissa placing,
ears open, ear twitch response, screen pull, screen cling/climb,
narrow stick placing reflex, wide stick placing reflex, auditory
startle, and popcorn behavior. Behaviors were scored as follows: 0
– no response; 1 – some response, weak and not coordinated; 2 –
moderate or incomplete response; 3 – full and complete response.
After completion of testing the pup was placed back in its home
cage.
2. Ultrasonic Vocalization (PNDs 9, 11, 13, 17). Pup
ultrasonic vocalization (USV) was measured by removing each
pup from its litter and placing it in a plastic cup that was
positioned under the microphone attached to the USV recording
system (Ultravox, Noldus Instruments, City). Testing was carried
out in a sound-attenuated testing chamber. Recording began
within 15 seconds after the pup was removed from its mother.
After the recording session the pup was kept separated from the
rest of the litter until all pups were tested. The USV detector was
set at 40 KHz and the audio filter was set at 8.5 and temperature
inside the testing chamber was recorded at the end of each session.
Recorded data were analyzed using the Noldus UltraVox
program. Altered number and duration of USVs were used to
asses pup distress.
3. Weaning (PND 21). On PND 21 pups were removed from
dam and ear notched for identification and left with littermates
until re-caging according to sex at puberty on PND 28.
4. Sociability (PND 25–26). Sociability and preference for
social novelty were tested as described previously [62]. Testing was
carried out in a 58639 cm opaque Plexiglas chamber divided into
three equal-sized compartments by two 22 cm high clear Plexiglas
walls. Each wall had a door that allowed movement between the
three compartments. During the an initial 10 minute habituation
session the injected test mouse was placed in the central
compartment and allowed to freely move between compartments.
After habituation the test mouse was removed and a unfamiliar
experimentally naı ¨ve male mouse was placed under a wire mesh
cup (Galaxy Cup, Kitchen Plus, http://www.kitchen-plus.com) in
one of the side compartments (side counterbalanced). The test
mouse was then placed in the central compartment and allowed to
freely move between compartments for another 10 minutes.
Percent time spent in the side compartment with the unfamiliar
mouse versus the opposite side chamber was calculated. A greater
percentage of time spent in the chamber with the stranger mouse
indicated a preference for social interaction, and was used as an
index of ‘‘sociability’’ as previously described [62].
5. Locomotor Activity (PND 27–28). Locomotor activity
was tested for 60 minutes using a TruScan Photo Beam open-field
activity arena for mice (Coulbourn Instruments., Allentown, PA)
as described previously [63]. The apparatus (27.5627.5637.5 cm)
detects movements in the three geometric planes by recording
infrared beam brakes resulting from mouse movement (e.g.,
horizontal movements, vertical movements, and distance traveled).
Each animal was tested individually in the chamber. The data
collected by the test session were then analyzed by TruScan
software.
6. Puberty Re-cage (PND 28). All animals were re-caged
according to their sex on postnatal day 28 with between 2–4 mice
per cage.
7. Elevated Plus Maze (PND 30). Fear and anxiety were
assessed using the elevated plus maze [64,65]. The maze was made
of opaque Plexiglas, with two open (306560.25 cm) and two
closed (306566 cm) arms emanating from a central platform
(565 cm), and elevated 60 cm above the floor. Each mouse was
placed onto the central platform and allowed 5 minute to freely
explore the maze. Distance traveled, number of entries into each
arm, time in open vs. closed arm and latency to first arm entry
were recorded by a video-tracking system (SMART, SD Instru-
ments, San Diego, CA). Percent time spent on the open versus the
closed arms of the maze was used as a measure of anxiety and fear.
8. Pre-pulse inhibition (PND 32–33). Pre-pulse inhibition
(PPI) of the auditory startle response was measured to assess
sensorimotor gating [66,67]. Mice were placed individually into
the auditory startle apparatus (SR-LAB, SD Instruments, San
Diego, CA, USA) and allowed to acclimate to background white
noise for 5 min. This was followed by a 20-minute PPI session
consisting of 50 test trials, 10 each for five different trial types
presented in a pseudorandom order with variable inter-trial
intervals of 5–20 milliseconds (ms). Trial types included: 120 dB
auditory stimulus alone, 120 dB stimulus with a 74, 82, or 90 dB
pre-pulse auditory stimulus. All pre-pulses were 20 ms long and
were presented 100 ms before the 120 dB stimulus. Broadband
pink noise was used for the acoustic stimulus. The change in
response from baseline to the 120 dB auditory stimulus was
compared to the change in response from baseline to pre-pulsed
120 dB auditory stimulus to measure sensory motor gaiting.
9. Spatial Memory and Learning in the Water Maze (PND
49–55). Spatial memory and learning were tested in a water
maze. The maze was 90 cm in diameter with a hidden 6 cm
square escape platform submerged 1 cm below the surface of the
water. Water temperature was maintained at 21uC. Maze
performance was monitored using an automated tracking system
(Polytrack, San Diego Instruments, Ca, USA). Before training
began, mice were given a single trial in which they were allowed to
swim to a visible escape platform raised 2 cm above the water
surface. This was immediately followed by four 90 sec training
trials with the platform hidden 1 cm below the surface of the
water. Briefly, mice were placed in the maze at one of three
quadrants not containing the platform, and were allowed to swim
in order to locate and mount the escape platform. These four test
trials were then repeated over four consecutive days. Latency to
mount the platform, swim distance, swim speed, and time spent
floating were measured. Animals who failed to reach the platform
during any trial received the maximum 90 s score for latency.
Inter-trial intervals were 10 minutes during which the mouse
waited in a warming cage. On the fifth day of training a ‘‘probe
trial’’ was given in which the platform was removed. Mice were
released at the center of the quadrant opposite the quadrant where
the platform was previously located, and the animals were allowed
to swim freely for 90 seconds. Percent time spent swimming in the
former escape platform quadrant was used to assess memory for
spatial location of the platform.
Histological Analysis
Once behavioral testing was complete a subset of mice were
sacrificed by an intraperitoneal injection of Euthasol (100 mg/kg)
for unbiased stereological examination to determine whether
misoprostol injections resulted in a possible loss of CA1
hippocampal neurons. A total of 23 males and 10 females were
used for these analyses. There were n=6, 5, 6, and 6 male mice in
the vehicle, 0.4, 4 and 40 mg/kg groups, respectively. For the
female mice there were n=5 in the vehicle and n=5 in the high
dose 40 mg/kg group. The hippocampus was selected for study
because it sensitive to a variety of developmental neurotoxins [68].
Mice were perfused with 20 ml of 0.1 M phosphate buffer (PB)
(pH 7.4) followed by a 20 minute gravity fed perfusion with 4%
paraformaldehyde (PFA) in 0.1 M sodium phosphate buffer. After
perfusion brains were removed and post-fixed for 1 hour in 4%
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solution for 1 hour and a 30% sucrose 0.1 M PB solution for
24 hours. After cryoprotection brains were flash frozen in dry ice
and stored at 280uC until sectioning. Brains were blocked and
sectioned at 50 mm on a sliding microtome (AO model 860). Slices
were preserved in 0.1% sodium azide in 0.1 M PB until mounting.
Every 5
th section was mounted starting approximately at Bregma
21.46 and ending at approximately Bregma 22.92 based on the
stereotaxic atlas The Mouse Brain in Stereotaxic Coordinates,
Second Edition [69], and cresyl violet stained. A total of 7
mounted sections for each subject were used for unbiased
stereological analysis of neuron number in the CA1 subregion of
the hippocampus using the optical fractionator probe (Stereo-
Investigator, Microbrightfield, Williston, VT).
Statistical Analysis
Data in figures represent mean 6 standard error (SE) of the
mean. Statistical analyses were carried out using version 18 of
SPSS (SPSS, Chicago, IL) and version of 9.2 of the SAS
programming language (SAS Institute, Cary, NC). For statistical
analyses 8 male pups and 8 female pups from each treatment
group were analyzed with total N=16 for each treatment group.
Data were analyzed using a mixed effects model that included
treatment and sex, with litter as a random effect. Repeated
measurements over time for each pup were considered by using
the autoregressive-1 (AR(1)) covariance structure. Individual post
hoc group comparisons were made using the Tukey-Kramer test
for multiple comparisons. Data were examined for homogeneity of
variance, and when assumptions of homogeneity of variance were
not met, data were analyzed using the Kruskal-Wallace nonpara-
metric analysis, followed by individual post hoc group comparisons
using the Mann-Whitney U adjusted for multiple comparisons.
The minimum level set for statistical significance was P,0.05.
Results
Treatment groups did not differ significantly in body weight on
the day of drug treatment (i.e., PND 7), or across the period of
behavioral testing. No signs of overt toxicity (e.g., lethargy,
vocalizations) were observed across treatment groups.
Behavioral Tests
A total sensory and motor developmental score was calculated
from the individual tests and the results are shown in Figure 1.
Statistical analysis of the Wahlsten neurodevelopmental test
battery did not show significant differences across treatment
groups in sensory or motor development (F3,64=.317, P=.813,
Effect Size=.009). Figure 2 shows the number of bouts of USV for
each group across PNDs 9, 11, 13 & 17. There were no statistically
significant effects of misoprostol treatment on USVs (F3,64=1.020,
P=.390, Effect Size=.049). Average escape latencies during
training in the Morris water maze are shown in Figure 3, but there
were no significant differences between groups (F3,64=.267,
P=.849, Effect Size=.013). Table 1 shows the mean +/2 SEs,
F values, probabilities and effect sizes for the main effect for the
remaining behavioral tests. As shown in Table 1, there were no
statistically significant differences in these tests between treatment
groups.
Hippocampal Cytoarchitecture
No gross morphological abnormalities in structure of the CA1
region of the hippocampus of male or female mice exposed to
misoprostol were found from examination of cresyl violet stained
brain sections. As shown in Figure 4, stereological analysis of the
number of pyramidal neurons in the CA1 subregion of the
hippocampus did not reveal any statistically significant differences
among treatment groups for males (F3,19=1.44, p=0.26) or
females (F1,8=0.27, p=0.62). There was no significant difference
between males and females (F1,27=1.54, p=0.26) and the sex by
treatment interaction was also not significant (F1,27=0.07,
p=0.79).
Discussion
The results of the present study failed to reveal significant
neurodevelopmental effects of neonatal subcutaneous injection
with 0.4, 4 or 40 mg/kg misoprostol on PND 7 in C57BL/6J mice.
This was true for tests of pre-weaning sensory and motor
development and adult locomotor activity. Tests of social
interaction and anxiety also failed to indicate any significant
neurodevelopmental effects of misoprostol. There was no evidence
for deficits in spatial learning or memory in the Morris water
maze. Finally, no gross effects on brain morphology were
observed, and there was no loss of hippocampal neurons in mice
exposed to misoprostol. The lack of neuronal loss in the
hippocampus is consistent with reports that misoprostol can be
neuroprotective and reduce apoptosis in several different cell types
[70–73]. However, the possibility remains that the fine structure of
the nervous system (e.g., dendritic spines, dendrite branching)
could be affected by misoprostol, and future research on this
possibility would be interesting in light of studies showing that
misoprostol can induce neurite retraction in vitro [39,40].
While it is possible that statistical power was insufficient to
detect significant group differences, group sizes fell within the
range that have been recommended for behavioral experiments in
mice [57]. In addition, effect sizes calculated for each of the tests
were small and did not support rejecting the null hypothesis of no
differences among treatment groups. Because our behavioral test
battery was not exhaustive there is the possibility that under
different testing conditions treatment effects may have been
observed. However, the test battery used in the current study was
chosen, in part, on the recommendations by Moy et al. concerning
appropriate behavioral tests for animal models of autism [56].
In the present study, the choice of PND 7 was to approximate
the time of human infant exposure to misoprostol which typically
occurs at the time of birth [55]. However, treatment with
Figure 3. Mean escape latency in the Morris water maze for the
four treatment groups. No group differences were statistically
significant.
doi:10.1371/journal.pone.0038911.g003
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affect critical windows of neurodevelopmental vulnerability
[23,36]. Studies evaluating developmental disorders linked to
maternal inflammation indicate that the most sensitive time period
of altered neurodevelopment occurs during gestation [74]. Further
there is in vitro evidence that misoprostol specifically disrupts
calcium homeostasis during early neuronal development resulting
in growth cone retraction [39]. Therefore future research to
evaluate earlier neonatal time points of exposure should be
conducted to determine whether the immature brain is more
vulnerable to the effects of misoprostol.
Another concern with the current study is whether the
subcutaneous route of drug administration resulted in sufficient
levels of misoprostol in the mouse pup (e.g. brain) to alter
behavioral development. The three log doses examined in this
study were meant to cover the range of exposures experience by
woman given misoprostol to induce labor with the highest dose,
40 mg/kg, exceeding the level used in pre-term abortion. Because
exposure to misoprostol occurs indirectly in the human infant as a
result of administration to the mother at the time of birth, it could
be assumed that direct exposure of pups to misoprostol by s.c.
injection would result in a higher concentration of misoprostol
within the pup, including brain, when compared to the unborn
child.
The lack of evidence in the current study for neurobehavioral
toxicity after in vivo exposure to misoprostol differs from the
results of in vitro studies by Tamiji et al. [39,40]. This could be
due to several factors such as differences in exposure levels and
physiological differences between in vivo and in vitro models. In
the study by Tamiji et al. [39] Neuro-2a cells directly exposed to
0.1 and 1 mM of misoprostol while in the current study neonatal
mice were exposed to 0.4, 4 and 40 mg/kg s.c.; thus it would be
expected that the actual exposure of neurons to misoprostol would
differ between the in vitro and in vivo models. Further the Neuro-
2a cell line used in the Tamiji et al. studies [39,40] has been shown
to differ importantly from primary cultures of intact neurons [75].
Specifically Neuro-2a cells showed a 20% decrease in expression
of voltage-gated sodium channels (VGSC) and an absence of N-
methyl-D-aspartate receptors (NMDAR) compared to intact
neurons, which led to differences in sensitivity to chemicals known
to produce neurotoxicity. This underscores the need to exercise
caution in interpreting data from in vitro studies, including
Table 1. Summary of main effects for statistical analyses of behavioral performance across treatment groups.
Test Parameter Test Day Dose N Mean ± SE F3,63
2,P
3 &E S
4 Values
Sociability % Time Socializing PND 25
1 0 16 58.564.0 F=.192
0.4 16 54.163.4 P=.901
4 16 56.664.5 ES=.010
40 16 55.764.9
Locomotor Total Distance Traveled PND 27 0 16 54786404 F=.633
0.4 16 50476280 P=.597
4 16 49076301 ES=.031
40 16 53826360
EPM % Time in Open Arm PND 30 0 16 21.162.9 F=.997
0.4 16 16.561.2 P=.401
4 16 20.561.8 ES=.047
40 16 20.562.2
PPI % Change in Startle from 90 db PND 32 0 16 16.365.6 F=.948
0.4 16 23.363.9 P=.423
4 16 25.162.4 ES=.045
40 16 20.963.1
1PND – postnatal day.
2F – F ratio from ANOVA.
3P – probability.
4ES – eta squared effects size estimate.
doi:10.1371/journal.pone.0038911.t001
Figure 4. Number of hippocampal CA1 pyramidal neurons
across treatment groups and sex. Four treatment groups (i.e.
vehicle, 0.4, 4.0 & 40 mg/kg misoprostol, s.c.) were analyzed for male
mice, and two treatment groups, the vehicle and high 40 mg/kg dose
group, were analyzed for females. No significant treatment effects, sex
differences or sex by treatment interaction were found.
doi:10.1371/journal.pone.0038911.g004
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strated that misoprostol was neuroprotective, and not neurotoxic,
at 50 and 500 mg/kg when given to PND 7 old rat pups in an in
vivo model of Hypoxic-Ischemic Encephalopathy (HIE) [76].
In summary, the present results do not provide support for
neurodevelopmental toxicity by misoprostol in neonatal mice at
the range of doses examined and when given at a time
approximating human birth. However, they do not prove that
misoprostol plays no role in the etiology of neurodevelopmental
disorders, including ASD. In fact, the timing of misoprostol
exposure during gestation appears to be critical [23,36]. When
high-dose misoprostol is given unsuccessfully early in gestation to
induce abortion, rather at the time of birth to induce labor, the
surviving fetus may develop Mo ¨bius syndrome, a disorder
characterized by congenital facial nerve paresis, congenital
limitation of abduction and a co-occurrence of autism like
symptoms [22,23,77]. However, there is no convincing evidence
that when given at the time of birth misoprostol is a risk factor for
neurodevelopmental disorders, including autism. This is supported
by both the current results and the results of the CHARGE study
in humans. Although the results of the current study are negative
concerning developmental neurotoxicity of misoprostol, they are
important none-the-less because of the large number of environ-
mental and teratogenic agents currently under suspicion for their
role in developmental disorders, and the need for scientific data
that can help focus future research efforts.
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